Cell Rep:新型候选药物或可有效治疗机体代谢综合征

2014-07-10 佚名 生物谷

近日,刊登在国际杂志Cell Reports上的一篇研究论文中,来自犹他大学的研究人员通过研究发现一种参与细胞内信号转导的酶类在代谢综合征的产生过程中扮演着重要角色,该研究或可帮助研究人员开发出治疗代谢综合征的新型靶向药物。 研究者Jared Rutter教授表示,我们希望在接下来的几年里进行人类的临床试验,目前获批的药物并不能治疗或者抑制大多数患者的代谢综合征症状,本文中对小鼠和大鼠模型研

近日,刊登在国际杂志Cell Reports上的一篇研究论文中,来自犹他大学的研究人员通过研究发现一种参与细胞内信号转导的酶类在代谢综合征的产生过程中扮演着重要角色,该研究或可帮助研究人员开发出治疗代谢综合征的新型靶向药物。

研究者Jared Rutter教授表示,我们希望在接下来的几年里进行人类的临床试验,目前获批的药物并不能治疗或者抑制大多数患者的代谢综合征症状,本文中对小鼠和大鼠模型研究的结果显示,代谢综合征在未来有望被彻底根除。代谢综合征可以增加心脏病、糖尿病及中风的风险,据估计其影响着25%的成人健康,公共卫生健康官员认为目前在美国及其它地方代谢综合征已经出现了流行的情况。

代谢综合征的主要特点就是脂肪酸以及甘油三酯的过量产生及储存;2009年研究者在对啮齿类的研究中发现了一种名为PASK的酶类,该酶类可以刺激脂肪酸和甘油三酯过量产生,PASK可以通过修饰其它蛋白质来发挥作用,进而改变这些修饰蛋白质的功能,PASK修饰的其中一种蛋白质名为SREBP-1c,该蛋白质可以作为产脂肪所有酶类的主要调节子。

利用候选药物,研究人员就可以通过修饰SREBP-1c来抑制PASK,而抑制SREBP-1c也会引发小鼠和大鼠肝脏中的脂肪酸及甘油三酯水平下降,而且在易于患糖尿病的动物中也发现了胰岛素耐受性和糖尿病的部分逆转。

研究者Rutter说道,我们希望这项研究不仅可以帮助理解机体的工作机制,而且开发出新型治疗人类疾病的疗法,研究人员并不知道是什么引发脂肪酸和甘油三酯的过量产生,那么下一步这将是一项新的研究重点,另外研究者也将去研究PASK激活SREBP-1c的分子机理。

原始出处

Wu X1, Romero D2, Swiatek WI1, Dorweiler I1, Kikani CK1, Sabic H1, Zweifel BS2, McKearn J2, Blitzer JT2, Nickols GA2, Rutter J3.PAS Kinase Drives Lipogenesis through SREBP-1 Maturation.Cell Rep. 2014 Jul 4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1868855, encodeId=e60f1868855d0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 18 09:07:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959099, encodeId=7e621959099d3, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Apr 14 10:07:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052393, encodeId=2cc2205239310, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27469, encryptionId=688a2e469f0, topicName=候选药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sat Dec 06 08:07:00 CST 2014, time=2014-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430467, encodeId=39e7143046e34, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jul 12 00:07:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619389, encodeId=e92616193892a, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jul 12 00:07:00 CST 2014, time=2014-07-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1868855, encodeId=e60f1868855d0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 18 09:07:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959099, encodeId=7e621959099d3, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Apr 14 10:07:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052393, encodeId=2cc2205239310, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27469, encryptionId=688a2e469f0, topicName=候选药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sat Dec 06 08:07:00 CST 2014, time=2014-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430467, encodeId=39e7143046e34, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jul 12 00:07:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619389, encodeId=e92616193892a, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jul 12 00:07:00 CST 2014, time=2014-07-12, status=1, ipAttribution=)]
    2015-04-14 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1868855, encodeId=e60f1868855d0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 18 09:07:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959099, encodeId=7e621959099d3, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Apr 14 10:07:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052393, encodeId=2cc2205239310, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27469, encryptionId=688a2e469f0, topicName=候选药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sat Dec 06 08:07:00 CST 2014, time=2014-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430467, encodeId=39e7143046e34, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jul 12 00:07:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619389, encodeId=e92616193892a, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jul 12 00:07:00 CST 2014, time=2014-07-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1868855, encodeId=e60f1868855d0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 18 09:07:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959099, encodeId=7e621959099d3, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Apr 14 10:07:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052393, encodeId=2cc2205239310, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27469, encryptionId=688a2e469f0, topicName=候选药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sat Dec 06 08:07:00 CST 2014, time=2014-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430467, encodeId=39e7143046e34, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jul 12 00:07:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619389, encodeId=e92616193892a, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jul 12 00:07:00 CST 2014, time=2014-07-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1868855, encodeId=e60f1868855d0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 18 09:07:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959099, encodeId=7e621959099d3, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Apr 14 10:07:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052393, encodeId=2cc2205239310, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27469, encryptionId=688a2e469f0, topicName=候选药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sat Dec 06 08:07:00 CST 2014, time=2014-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430467, encodeId=39e7143046e34, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jul 12 00:07:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619389, encodeId=e92616193892a, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jul 12 00:07:00 CST 2014, time=2014-07-12, status=1, ipAttribution=)]

相关资讯

Front Behav Neurosci:贪官大脑与我们有何不同:药物或可抑制腐败

概念图 香港《南华早报》网站7月5日刊登题为《贪官的大脑,与我们有何不同?》的报道称,人们会毫不犹豫地接受贿赂,还是会再三深思?科学家认为,这个问题或许 可以在左脑中找到答案。这一说法促使外界讨论是否可以利用药物或治疗方法来抑制腐败倾向。 科学界一直在寻找一种神经机制,希望借此解释为何人们的行为会偏离社会规范。 内地行为神经科学家最近重点研究了大脑左侧额下回稍上方的

可减轻哮喘发作与过敏的药物

一种被称作quilizumab的实验性药物或能通过在病人中降低某种叫做E型免疫球蛋白(IgE)的炎性蛋白浓度从而减少哮喘及过敏症状。 早期阶段的临床试验提示,该药会在某一天成为一种对数百万罹患严重哮喘或过敏者有效的治疗选项。目前,只有一种哮喘治疗是以IgE作为标靶的,但它对该炎症蛋白的产生没有影响,这意味着患者需要接受常规剂量的该药物才能让IgE浓度一直得以控制。Gail Gauvreau及其同

FDA承诺加快对Boehringer肺部疾病药物审批

FDA最近表示将对勃林格殷格翰公司开发的用于治疗肺部疾病特发性肺纤维化(idiopathic pulmonary fibrosis (IPF))药物nintedanib进行优先审核。这一决定也将加快其上市的审批流程并在与InterMune公司相似药物竞争中迎头赶上。勃林格殷格翰公司进行了两项超过1000名患者参与的临床上拿起研究,分别发现nintedanib将患者肺功能年平均丧失率降低了4

Biomaterials:新型药物载体能定向将青蒿素运载进入肿瘤细胞

中国科学院强磁场科学中心双聘研究员陈乾旺、中国科学技术大学生命科学学院教授郭振副、安徽医科大学副主任医师王海宝三课题组合作,利用肿瘤细胞内环境的调控,发展了具有pH响应性的多功能药物载体,它能够将疏水药物青蒿素输送到肿瘤细胞内,同时释放出可作为青蒿素抗癌的诱导剂的Fe2+,从而大大提高了抗癌药效。相关研究在线发表在《生物材料》(Biomaterials)上。目前临床上广泛使用的抗癌药物仍为人工合成

Neuron:阻断恐惧记忆的新型药物

近日,刊登在国际杂志Neuron上的一篇研究论文中,来自艾默里大学的研究人员通过研究鉴别出了一种新型药物,其可以使得小鼠大脑中的可怕记忆变得不再持久,该项研究或为揭示创伤后应激障碍(PTSD,Post Traumatic Stress Disorder)的发病机制以及开发新型靶向性疗法提供一定的希望。 这种药物名为奥沙奈坦,其可以以控制恐惧记忆形成合并的大脑区域中的大脑细胞进行靶向作用,研究者K

Jazz继续开发开发罕见病药物defibrotide

Jazz生物医药公司在去年收购了著名罕见病药物研究公司Gentium公司后,立刻开始了一系列动作。现在,Jazz公司开始将目光投向一项此前被Gentium公司长期搁置的治疗静脉闭塞症药物defibrotide。此前Gentium公司与西格玛公司曾经达成一项总价值2500万美元的合作协议以研发defibrotide。然而在2013年欧洲医药管理部门拒绝了其上市申请并列举出defibrotide从